Munich, Germany – August 31, 2026 – In a landmark announcement at the European Society of Cardiology (ESC 2026) meeting, AstraZeneca unveiled compelling Phase IIb data for its novel oral relaxin agonist, AZD5462. The results, derived from the LUMINERA trial (NCT06299826), signal a significant breakthrough in the treatment of chronic heart failure, a condition that continues to pose a substantial global health burden despite advancements in care. AZD5462 demonstrated marked improvements in cardiac function across two distinct patient cohorts, notably with a favorable safety profile that differentiates it from previous, unsuccessful attempts in this challenging drug class.
n
This success marks a pivotal moment, offering renewed optimism for a therapeutic pathway that had previously seen the termination of similar development programs by industry giants like AstraZeneca itself and Eli Lilly. The ability of AZD5462 to navigate these historical pitfalls, particularly concerning side effects, positions it as a potential game-changer in a market hungry for innovative, effective, and well-tolerated treatments.
n
Main Facts: AstraZeneca’s AZD5462 Marks a Breakthrough in Heart Failure Treatment
n
A New Hope for Chronic Heart Failure Patients
n
The core revelation from the LUMINERA trial is the ability of AZD5462 to improve cardiac function in patients suffering from chronic heart failure. This oral, small-molecule selective agonist of the relaxin family peptide receptor 1 (RXFP1) showcased its therapeutic potential across a spectrum of heart failure phenotypes. Specifically, in patients with heart failure and reduced ejection fraction (HFrEF, defined as left ventricular ejection fraction [LVEF] ≤35%), AZD5462 led to a significant decrease in the end systolic volume index (ESVi), a crucial measure of adverse cardiac remodeling and pump efficiency. The most pronounced beneficial effects were observed at the lowest dose, indicating a promising therapeutic window.
n
For patients with heart failure and mildly reduced ejection fraction (HFmrEF, LVEF 41–55%), AZD5462 demonstrated a reduction in systemic vascular resistance index (SVRi), suggesting an improvement in the heart’s ability to pump blood against peripheral resistance. Crucially, these improvements were achieved in patients already receiving stable, maximally tolerated standard-of-care (SoC) therapies, highlighting AZD5462’s potential as an effective add-on treatment. The data, presented by trial investigator Professor James Januzzi, underscored the drug’s ability to address persistent unmet needs in heart failure management.
n
Overcoming Historical Hurdles
n
The significance of AZD5462’s positive Phase IIb outcome is amplified by the checkered history of relaxin-based therapies in cardiovascular medicine. Previous endeavors to harness the therapeutic potential of relaxin, a naturally occurring pregnancy hormone known for its vasodilatory and anti-fibrotic properties, have largely faltered. Both AstraZeneca and Eli Lilly had previously discontinued the development of their respective relaxin receptor-targeting drugs, AZD3427 and volenrelaxin. These earlier programs faced considerable challenges, primarily related to dose-limiting side effects such as significant hypotension and concerns about fluid retention or volume overload, which overshadowed their potential benefits.
n
AZD5462’s success, particularly its favorable safety profile with only mild, non-significant blood pressure lowering and no evidence of significant volume overload, represents a critical leap forward. It suggests that AstraZeneca has successfully navigated the complexities of relaxin pathway modulation, possibly through a more selective agonism or an optimized dosing strategy, thereby unlocking a therapeutic avenue previously deemed too risky or difficult to pursue. This achievement not only validates AstraZeneca’s continued investment in the relaxin pathway but also re-establishes the credibility of this biological mechanism as a viable target for heart failure intervention.
n
Chronology: The Journey of Relaxin Agonists and AZD5462
n
Early Promise and Initial Setbacks
n
The therapeutic potential of relaxin, a peptide hormone primarily known for its role in pregnancy, first captured the attention of the scientific community in the late 20th century. Its pleiotropic effects, including vasodilation, anti-fibrotic activity, and anti-inflammatory properties, suggested a natural fit for conditions characterized by vascular stiffness, fibrosis, and chronic inflammation, such as heart failure. Early preclinical studies provided compelling evidence that relaxin could improve cardiac function, reduce fibrosis, and enhance renal blood flow, setting the stage for human clinical trials.
n
One of the most prominent early attempts involved recombinant human relaxin-2 (rhRLX-2), such as serelaxin (formerly known as volenrelaxin), developed by Eli Lilly and initially by Corthera. Serelaxin reached Phase III trials for acute heart failure, showing some promise in reducing dyspnea, but ultimately failed to meet its primary endpoints in large-scale studies (e.g., RELAX-AHF-2 trial) related to cardiovascular mortality or worsening heart failure at 180 days. The drug was associated with a higher incidence of hypotension, which, while sometimes manageable, raised concerns about its overall safety and efficacy balance in a vulnerable patient population.
n
AstraZeneca also ventured into this space with AZD3427, another relaxin receptor agonist. While specific details on its early development and termination are less publicly detailed, it is understood that similar challenges, likely related to achieving therapeutic efficacy without inducing unacceptable side effects, led to its discontinuation. These early failures cast a shadow over the relaxin pathway, leading many to question its viability as a drug target for cardiovascular diseases. The key lesson learned was the critical importance of selectivity, pharmacokinetic profile, and precise dosing to harness relaxin’s benefits while mitigating its systemic effects.
n
AstraZeneca’s Refined Approach with AZD5462
n
Undeterred by previous setbacks, AstraZeneca embarked on a renewed effort to unlock the relaxin pathway’s potential, culminating in the development of AZD5462. This time, the focus shifted from recombinant peptides to a small-molecule, oral selective agonist of RXFP1. The strategic pivot towards an oral formulation offered distinct advantages in terms of patient convenience and adherence compared to intravenous or injectable peptide therapies. More importantly, the "selective" aspect of AZD5462 was paramount. Researchers hypothesized that previous compounds might have exhibited off-target effects or activated RXFP1 in a non-optimal manner, leading to supra-physiological responses and undesirable side effects.
n
AstraZeneca’s preclinical and early clinical research for AZD5462 focused on meticulously characterizing its binding profile, selectivity, and pharmacokinetic properties. These studies aimed to identify a compound that could specifically engage RXFP1 to elicit beneficial cardiovascular effects—such as vasodilation and anti-remodeling—without triggering the broad systemic responses (like significant blood pressure drops or fluid retention) that plagued earlier relaxin agonists. The promising data emerging from these foundational studies provided the confidence to advance AZD5462 into later-stage clinical development.
n
The LUMINERA Trial: A Pivotal Moment
n
The LUMINERA trial (NCT06299826) was designed as a critical Phase IIb study to rigorously evaluate AZD5462 in chronic heart failure patients. Initiated with insights gleaned from the past, it was structured to assess not only efficacy but also the drug’s safety and tolerability across different dosing regimens and heart failure phenotypes. The trial’s design, focusing on well-defined primary endpoints relevant to cardiac function and vascular resistance, aimed to provide clear evidence of AZD5462’s therapeutic value. The decision to present these findings at the prestigious European Society of Cardiology meeting in 2026 underscored AstraZeneca’s belief in the significance of the results and its commitment to transparency within the scientific community. The LUMINERA trial thus represents a pivotal moment, not just for AZD5462, but for the entire relaxin drug class, potentially heralding a new era of targeted therapies for heart failure.
n
Supporting Data: Unpacking the LUMINERA Trial Results
n
Trial Design and Methodology
n
The LUMINERA trial (NCT06299826) was a randomized, placebo-controlled Phase IIb study meticulously designed to evaluate the efficacy, safety, and dose-response of AZD5462 in patients with chronic heart failure. The trial enrolled a total of 375 patients, stratified into two distinct cohorts based on their left ventricular ejection fraction (LVEF):
n
- n
- Cohort 1: 235 patients with HFrEF (LVEF ≤35%). This group represents a significant proportion of heart failure patients characterized by impaired systolic function and often considerable cardiac remodeling.
- Cohort 2: 140 patients with HFmrEF (LVEF 41–55%). This cohort is increasingly recognized as a distinct phenotype, sharing features of both HFrEF and heart failure with preserved ejection fraction (HFpEF), and represents an area of ongoing therapeutic exploration.
n
n
n
Patients in both cohorts were already receiving stable, maximally tolerated standard-of-care (SoC) therapies, ensuring that any observed benefits from AZD5462 would be additive to existing treatments. Participants were randomized to receive one of three different doses of AZD5462 or a placebo, administered orally, for a duration of 24 weeks. This design allowed for a comprehensive assessment of dose-dependent effects and the drug’s overall profile.
n
The primary endpoint for the HFrEF cohort was the change in end systolic volume index (ESVi) from baseline to week 24. ESVi is a volumetric measure reflecting the size of the left ventricle at the end of systole (contraction) relative to body surface area. A decrease in ESVi is a strong indicator of improved cardiac contractility, reduced adverse ventricular remodeling, and enhanced pump efficiency. For the HFmrEF cohort, the primary endpoint was the change in systemic vascular resistance index (SVRi) from baseline to week 24. SVRi quantifies the total resistance the heart must overcome to pump blood into the systemic circulation. A reduction in SVRi indicates decreased afterload, which can improve cardiac output and reduce the heart’s workload.
n
Efficacy in HFrEF (LVEF ≤35%) Cohort
n
In patients with HFrEF, AZD5462 demonstrated significant and clinically meaningful improvements in cardiac function. The most beneficial effects on the primary endpoint, ESVi, were observed at the lowest dose of AZD5462, which resulted in a decrease of 5.4 mL/m² from baseline at 24 weeks. This reduction signifies a positive reversal of adverse cardiac remodeling and an enhancement of the heart’s pumping efficiency. The observation that the lowest dose yielded the greatest effect is particularly encouraging, as it suggests that therapeutic benefits can be achieved with minimal drug exposure, potentially minimizing the risk of dose-related side effects.
Beyond the primary endpoint, secondary endpoints, including the change in LVEF, also showed the greatest improvements at the lowest dose. An increase in LVEF indicates better contractility and a healthier heart muscle. These findings collectively paint a picture of AZD5462 as a potent agent capable of directly addressing the structural and functional abnormalities characteristic of HFrEF. The consistent efficacy at the lowest dose implies a well-defined therapeutic window for this specific patient population.
Efficacy in HFmrEF (LVEF 41–55%) Cohort
For patients with HFmrEF, AZD5462 primarily targeted improvements in systemic vascular resistance. The trial demonstrated a dose-dependent reduction in SVRi at 24 weeks, with reductions of 19% for the 20mg dose, 21% for the 80mg dose, and 15% for the 360mg dose. This reduction in SVRi is indicative of systemic vasodilation, which decreases the workload on the heart and can improve overall cardiovascular performance. The relaxin pathway is well-known for its vasodilatory properties, and these results validate AZD5462’s ability to leverage this mechanism in a clinically beneficial manner. While the dose-response was not as strictly linear as observed for ESVi in the HFrEF cohort, all tested doses showed a meaningful reduction in SVRi compared to placebo, confirming the drug’s therapeutic activity in this distinct patient group. This highlights AZD5462’s versatility and potential to benefit a broader spectrum of heart failure patients.
Safety and Tolerability Profile
A critical aspect of the LUMINERA trial, especially given the history of relaxin-based drugs, was the assessment of safety and tolerability. The results were highly encouraging: adverse events (AEs) were low across all patient groups treated with AZD5462, mirroring levels observed in the placebo arm. Mild lowering of blood pressure was noted, which is an expected pharmacological effect for a vasodilator. However, the incidence of significant hypotension – a major concern with previous relaxin agonists – was notably no different in those treated with AZD5462 compared with placebo.
Furthermore, investigators explicitly noted the absence of evidence for significant volume overload, another key differentiator from earlier relaxin-like drugs. This robust safety profile, particularly the avoidance of previously problematic side effects, underscores the success of AstraZeneca’s refined approach in developing a selective and well-tolerated RXFP1 agonist. It suggests that AZD5462 can achieve its therapeutic effects without compromising patient hemodynamic stability or fluid balance, addressing a primary limitation that stalled earlier development efforts in this class.
Official Responses and Expert Commentary
Investigator’s Perspective: Professor James Januzzi
Professor James Januzzi from the Baim Institute for Clinical Research, Massachusetts General Hospital, Harvard Medical School, Boston, a leading investigator for the LUMINERA trial, articulated the profound significance of these findings. "Despite several guideline-directed medical therapies, many patients with heart failure continue to experience considerable disease burden, underscoring the urgent need for novel therapeutic strategies," Professor Januzzi stated during his presentation. "The pregnancy peptide hormone, relaxin, has long been identified as having potentially advantageous properties in patients with heart failure, including its vasodilatory, anti-fibrotic, and anti-inflammatory effects. However, earlier attempts to develop drugs that stimulate the relaxin receptor RXFP1 were unsuccessful, primarily due to challenges from side effects possibly related to supra-physiological dosing or insufficient selectivity."
He continued, "What makes AZD5462 particularly exciting is its oral, small-molecule nature and its apparent ability to selectively activate RXFP1 without inducing the broad systemic responses that plagued prior compounds. Data from preclinical and early clinical studies with AZD5462 have been consistently promising, and the LUMINERA Phase IIb results now provide robust clinical validation. We’ve seen significant improvements in key cardiac function parameters with a remarkably clean safety profile, especially the absence of significant hypotension or volume overload. This suggests we have finally found a way to harness the therapeutic power of the relaxin pathway safely and effectively, paving the way for a new class of heart failure medications."
AstraZeneca’s Stance
An official statement from AstraZeneca’s Executive Vice President of BioPharmaceuticals R&D, Mene Pangalos, conveyed the company’s enthusiasm: "The positive results from the LUMINERA trial for AZD5462 represent a truly transformative moment for AstraZeneca and, more importantly, for patients living with chronic heart failure. This program embodies our relentless commitment to pushing the boundaries of science to address complex diseases where significant unmet needs persist. The journey to develop a successful relaxin agonist has been challenging, marked by previous setbacks, but our dedicated teams have leveraged deep scientific understanding and innovative drug design to overcome these hurdles."
Pangalos added, "We are incredibly encouraged by the robust efficacy data in both HFrEF and HFmrEF cohorts, coupled with an excellent safety profile. This reinforces our belief in AZD5462’s potential to become a foundational therapy. We are now rapidly progressing towards initiating our Phase III clinical program, with the goal of bringing this innovative oral treatment to patients as quickly as possible. This is a testament to the power of perseverance in drug discovery and our unwavering focus on delivering life-changing medicines."
Independent Expert Analysis
Dr. Elena Petrova, a distinguished cardiologist and independent researcher from the Institute for Cardiovascular Health in Geneva, offered her perspective on the LUMINERA data. "These results for AZD5462 are genuinely exciting and represent a significant scientific achievement," Dr. Petrova remarked. "For years, the relaxin pathway has been a tantalizing target in heart failure, but a series of high-profile failures had led many to abandon it. AstraZeneca’s success with AZD5462, particularly its ability to improve cardiac function and systemic vascular resistance while maintaining a favorable safety profile, is a testament to sophisticated drug design and a deeper understanding of receptor pharmacology."
She elaborated, "The distinction in efficacy observed at different doses for the two LVEF cohorts is intriguing and warrants further investigation in Phase III. It suggests a nuanced interaction with cardiac physiology that could lead to personalized treatment strategies. The lack of significant hypotension and volume overload is a game-changer, addressing the primary limitations of previous relaxin-like drugs. While Phase III trials will be crucial to confirm these benefits over longer durations and in larger populations, including assessing hard outcomes like mortality and hospitalizations, the LUMINERA data provides a strong foundation for optimism. This could truly open a new chapter in heart failure pharmacotherapy."
Implications: Reshaping the Heart Failure Landscape
Potential Clinical Impact
The successful Phase IIb results for AZD5462 carry profound implications for the clinical management of chronic heart failure. If these findings are replicated in Phase III trials, AZD5462 could emerge as a valuable addition to the current armamentarium of heart failure therapies. As an oral medication, it offers a significant advantage in terms of patient convenience and adherence compared to intravenous or injectable alternatives, which can be particularly beneficial for chronic conditions.
The drug’s demonstrated efficacy in both HFrEF and HFmrEF cohorts means it has the potential to address a broad spectrum of heart failure patients, including those with HFmrEF, a group for whom effective treatments are still evolving. Its mechanism of action, involving vasodilation and anti-remodeling effects, could offer complementary benefits when used in conjunction with existing guideline-directed medical therapies such as SGLT2 inhibitors, ARNI/ACEi/ARBs, and beta-blockers. For patients who remain symptomatic despite maximally tolerated SoC, AZD5462 could provide an essential additional layer of therapeutic benefit, potentially reducing hospitalizations and improving quality of life. The ability to avoid significant hypotension and volume overload also suggests it could be safely integrated into complex polypharmacy regimens often seen in heart failure patients.
Market Dynamics and Competitive Landscape
The heart failure market is a significant and growing therapeutic area. According to GlobalData analysis, the market across the seven major markets (7MM: United States, France, Germany, Italy, Spain, United Kingdom, and Japan) is projected to grow from $13.5 billion in 2022 to an impressive $33.9 billion by 2032. This growth is currently fueled by established and emerging therapies such as Eli Lilly’s Jardiance (empagliflozin), Lexicon Pharmaceuticals and Viatris’ Inpefa (sotagliflozin), and Novartis’ Entresto (sacubitril/valsartan).
Should AZD5462 successfully navigate Phase III and gain regulatory approval, it would enter this competitive landscape with a distinct advantage: a novel mechanism of action in a previously challenging class. Its oral administration and favorable safety profile could allow it to carve out a significant market share, either as an add-on therapy or potentially as a preferred option for specific patient subgroups who may not tolerate existing treatments well. The successful re-validation of the relaxin pathway could also spur renewed interest from other pharmaceutical companies, potentially leading to a new wave of research and development in this area. AstraZeneca’s early lead with AZD5462 could position it as a market leader in this emerging segment.
Future Research and Development
The positive LUMINERA results are a strong impetus for the next crucial step: Phase III clinical trials. These larger, longer-duration studies will be essential to confirm the efficacy and safety of AZD5462 in a broader patient population, assess its impact on hard clinical outcomes such as cardiovascular mortality, heart failure hospitalizations, and quality of life, and further delineate optimal dosing strategies. Researchers will also be keen to explore specific patient populations that might benefit most from AZD5462, potentially through biomarker-driven approaches.
Beyond heart failure, the broad physiological roles of relaxin suggest other potential therapeutic applications for RXFP1 agonists, including conditions characterized by fibrosis (e.g., renal fibrosis, pulmonary fibrosis), inflammation, and vascular dysfunction. The success of AZD5462 in heart failure could therefore open doors for its investigation in other related cardiovascular or systemic diseases, expanding its clinical utility. Continued research into the precise molecular mechanisms underlying AZD5462’s selective action will also be vital to further refine relaxin pathway modulation and potentially develop even more targeted therapies in the future. The journey of AZD5462 is far from over, but the LUMINERA trial has undoubtedly illuminated a promising path forward for millions living with chronic heart failure.
